A COMPARATIVE MULTICENTER STUDY OF THE EFFECTS OF CONTINUOUS LOW-DOSE ESTRADIOL RELEASED FROM A NEW VAGINAL RING VERSUS ESTRIOL VAGINAL PESSARIES IN POSTMENOPAUSAL WOMEN WITH SYMPTOMS AND SIGNS OF UROGENITAL ATROPHY

被引:74
作者
HENRIKSSON, L
STJERNQUIST, M
BOQUIST, L
ALANDER, U
SELINUS, I
机构
[1] LUND UNIV,DEPT OBSTET & GYNECOL,LUND,SWEDEN
[2] UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN
[3] KABI PHARMACIA AB THERAPEUT,DEPT CLIN RES,UPPSALA,SWEDEN
关键词
UROGENITAL SYMPTOMS; POSTMENOPAUSE; ESTRADIOL; ESTRIOL;
D O I
10.1016/0002-9378(94)90074-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: Our purpose was to study the efficacy, safety, and acceptability of a new estradiol-releasing (6.5 to 9.5 mu g per 24 hours) silicone rubber vaginal ring compared with Ovesterin 0.5 mg estriol vaginal pessaries. STUDY DESIGN: Gynecologic clinical status, vaginal pH, cytologic characteristics, and occurrence of bacteriuria were determined before starting and after 3 and 12 weeks of treatment in 146 postmenopausal women. RESULTS: Both treatments alleviated the subjective and objective symptoms of estrogen deficiency excellently, and both were equally effective at restoring the vaginal pH to levels normally seen in fertile women (< 5.5). Vaginal cytologic studies showed a significant difference in maturation value in favor of the estradiol-releasing silicone rubber vaginal ring, as measured by the pathologist's assessment of the proliferation of the vaginal mucosa. A total of 77% of users were classified as responders, compared with 39% in the pessary group. Both treatments were well accepted. The administration of the pessary was associated with a significantly higher (p < 0.001) incidence of discomfort than that of the ring, which was given better (p < 0.001) rating by the patients at the 12-week visit. A strong preference (p < 0.001) for the ring was shown by patients with previous experience with pessaries. CONCLUSION: Treatment of urogenital symptoms in postmenopausal women with an estradiol-releasing vaginal ring is shown to be an effective and safe method, exhibiting advantages over treatment with estriol vaginal pessaries.
引用
收藏
页码:624 / 632
页数:9
相关论文
共 8 条
[1]  
ANDERSSON SB, 1992, 20230F KABI PHARM AB
[2]  
BOMAN K, 1990, ANTICANCER RES, V10, P173
[3]   VAGINAL RINGS FOR CONTINUOUS LOW-DOSE RELEASE OF ESTRADIOL IN THE TREATMENT OF UROGENITAL ATROPHY [J].
HOLMGREN, PA ;
LINDSKOG, M ;
VONSCHOULTZ, B .
MATURITAS, 1989, 11 (01) :55-63
[4]  
HUSTIN J, 1977, ACTA CYTOL, V21, P225
[5]  
JOHANNSON CJ, 1992, 20466F KAB PHARM AB
[6]   THE DOSE-EFFECT RELATIONSHIP BETWEEN UNOPPOSED ESTROGENS AND ENDOMETRIAL MITOTIC RATE - ITS CENTRAL ROLE IN EXPLAINING AND PREDICTING ENDOMETRIAL CANCER RISK [J].
KEY, TJA ;
PIKE, MC .
BRITISH JOURNAL OF CANCER, 1988, 57 (02) :205-212
[7]   ESTRADIOL-RELEASING VAGINAL RING FOR TREATMENT OF POSTMENOPAUSAL UROGENITAL ATROPHY [J].
SMITH, P ;
HEIMER, G ;
LINDSKOG, M ;
ULMSTEN, U .
MATURITAS, 1993, 16 (02) :145-154
[8]   EVALUATION OF THE URETHRAL MUCOSA BEFORE AND AFTER ESTROGEN-TREATMENT IN POSTMENOPAUSAL WOMEN WITH A NEW SAMPLING TECHNIQUE [J].
ULMSTEN, U ;
STORMBY, N .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1987, 24 (03) :208-211